For the quarter ending 2025-09-30, TNGX made $53,811K in revenue. $15,884K in net income. Net profit margin of 29.52%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 53,811 | 3,181 | 5,392 | 10,154 |
| Research and development | 30,815 | 32,807 | 36,442 | 36,885 |
| General and administrative | 8,924 | 11,341 | 11,480 | 10,841 |
| Total operating expenses | 39,739 | 44,148 | 47,922 | 47,726 |
| Operating income (loss) | 14,072 | -40,967 | -42,530 | -37,572 |
| Interest income | 1,097 | 1,239 | 1,614 | 2,027 |
| Other income, net | 705 | 910 | 1,074 | 1,885 |
| Total other income, net | 1,802 | 2,149 | 2,688 | 3,912 |
| Pretax income (loss) | 15,874 | -38,818 | -39,842 | -33,660 |
| Benefit from (provision for) income taxes | -10 | 35 | 34 | 51 |
| Net income (loss) | 15,884 | -38,853 | -39,876 | -33,712 |
| Unrealized gain (loss) on marketable securities | - | - | - | 38 |
| Comprehensive loss | - | - | - | -32,538 |
| Net loss per common share - basic | 0.14 | -0.35 | -0.36 | -0.307 |
| Net loss per common share - diluted | 0.13 | -0.35 | -0.36 | -0.307 |
| Weighted-average common stock outstanding - basic | 110,966,345 | 110,540,836 | 110,301,256 | 239,780.333 |
| Weighted-average common stock outstanding - diluted | 117,782,074 | 110,540,836 | 110,301,256 | 239,780.333 |
Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. (TNGX)